OLIVE PHARMASCIENCE LIMITED

Daman, IndiaFEI 3009681646

OLIVE PHARMASCIENCE LIMITED is a drug establishment in Daman, India, registered with the US FDA under FEI 3009681646. Its registered operations are: Drug manufacture. 3 EU/UK GMP certificates are matched to this site, 2 inspected within the last three years; 1 has since been withdrawn by the issuing authority. FDA has published 2 inspection outcomes for this FEI; the most recent, ended 31 Mar 2017, was classified voluntary action indicated (VAI).

Sources: FDA Drug Establishments Current Registration Site (checked 16 Nov 2026); FDA Data Dashboard (inspections); EudraGMDP; MHRA GMDP. Methodology

Cite as: PharmaTek, “OLIVE PHARMASCIENCE LIMITED: FDA registration, inspection and GMP record (FEI 3009681646)”, record as of 16 Nov 2026, pharmatek.co.uk/manufacturing-sites/olive-pharmascience-limited-daman-3009681646

Registered operations

Business operations this establishment declares in its FDA registration. Registration is not an approval and says nothing about EU or UK GMP status.

Drug manufacture

GMP documents matched to this site (3)

DocumentAuthorityInspectionSource
FT046/MH/001/2025
GMP certificate
Competent authority of Portugal8 Mar 2024
within 3-year review window
EudraGMDP
FT046/MH/001/2024
GMP certificate
Competent authority of Portugal8 Mar 2024
within 3-year review window
EudraGMDP
FT046/001/2018
GMP certificate
Competent authority of Portugal10 Nov 2017
Withdrawn by the authority on 1 Aug 2025
Register note: Replaced by GMP certificate no. FT046/001/2018 ref key 168341
EudraGMDP

A GMP document is matched to this site when its address names the site's street and its city or postcode. In our latest internal review 59 of 60 sampled matches were the right site (not yet independently reviewed; measured match quality). Check the certificate's own address before relying on it. The three-year review window is the EMA guideline default after an inspection, not an official expiry date.

FDA inspection outcomes (2)

Inspection endedOutcomeProgramme areaCitations posted
31 Mar 2017VAI · Voluntary action indicatedDrug Quality AssuranceNo
20 Sept 2012VAI · Voluntary action indicatedDrug Quality AssuranceYes

FDA Data Dashboard, joined on the FEI. NAI: no objectionable conditions found. VAI: objectionable conditions found, but not serious enough for regulatory action. OAI: regulatory or administrative action recommended. A classification describes one inspection on one date; FDA publishes it only once final and does not publish every inspection. FDA firm profile

Form 483 observations (3)

Inspection ended 20 Sept 2012: 3 observations
  • 21 CFR 211.100(b) SOPs not followed / documented
  • 21 CFR 211.67(a) Cleaning / Sanitizing / Maintenance
  • 21 CFR 211.100(a) Absence of Written Procedures

FDA Data Dashboard (inspection citations), joined on the FEI. Each line is the regulation cited and FDA's short description, not the full observation text. A Form 483 lists an investigator's observations at the close of an inspection; it is not a final agency determination, and FDA does not publish citations for every inspection.

What this page does not show

  • Which substances are made here: DMFs and CEPs are filed by organisations, not sites, so we do not link substances to this site.
  • Capacity, scale, price or current availability: no regulator publishes these.
  • The full text of a Form 483 or warning letter: FDA's dashboard gives the regulation cited and a short description only.
For suppliers

Is this OLIVE HEALTHCARE?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.